2H-Benzotriazole Derivative for Treating Premature Ejaculation
Summary
USPTO published patent application US20260098034A1 for a 2H-benzotriazole derivative compound and pharmaceutical composition for treating premature ejaculation. The novel benzisothiazole compound demonstrated superior anti-premature ejaculation activity compared to dapoxetine in in-vivo testing. Six inventors are listed with a filing date of August 23, 2023.
What changed
USPTO published patent application US20260098034A1 disclosing a 2H-benzotriazole substituted benzisothiazole compound with formula (I) and pharmaceutical compositions containing the compound. The invention specifically relates to applications of the compound in preparing medicines for treating and/or preventing premature ejaculation. In-vivo activity testing demonstrated the compound exhibits significantly higher anti-premature ejaculation activity compared to the marketed drug dapoxetine.
For pharmaceutical companies developing premature ejaculation treatments, this patent application represents potential future competition for dapoxetine-based therapies. Drug manufacturers should consider this application's claims when assessing R&D pipelines and freedom-to-operate analyses for related compounds. The novel structural class may offer improved therapeutic efficacy, creating potential market differentiation opportunities or blocking patents.
What to do next
- Monitor USPTO patent database for examination updates
- Review patent claims for freedom-to-operate implications
- Assess potential market impact on premature ejaculation treatments
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
2H-BENZOTRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Application US20260098034A1 Kind: A1 Apr 09, 2026
Inventors
Peng WANG, Yuqing ZHAO, Yan ZHOU, Lirong ZHANG, Jie ZHOU, Xin ZHOU
Abstract
The invention discloses a benzisothiazole compound as well as a pharmaceutical composition and application thereof, belongs to the technical field of medicines, and particularly relates to a 2H-benzotriazole substituted benzisothiazole compound with a novel structure as shown in a formula (I), a pharmaceutical composition containing the compound and application of the compound in preparation of medicines for treating and/or preventing premature ejaculation. Through in-vivo activity test research, the compound has obviously higher anti-premature ejaculation activity than the on-sale drug dapoxetine.
CPC Classifications
C07D 413/14 A61K 31/454 A61K 31/496 A61P 15/00 C07D 417/14
Filing Date
2023-08-23
Application No.
19112922
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.